← All trials
NCT06995430
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 7, 2025
- Primary completion
- Dec 10, 2025
- Completion date
- Dec 10, 2025
- First posted
- May 29, 2025
- Last posted
- Nov 24, 2025
- Enrollment
- 226
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- GlaxoSmithKlineLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.